PC
BCRX icon

Paulson & Co’s BioCryst Pharmaceuticals BCRX Stock Holding History

Paulson & Co’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-350,000
Closed -$2.94M – 111
2017
Q1 		$2.94M Hold
350,000
– – 0.04% 80
2016
Q4 		$2.22M Buy
+350,000
New +$1.82M 0.03% 83

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Paulson & Co's BCRX Position: Q3 2017 in Review

Paulson & Co sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2017, closing a stake of 349,500 shares — an estimated $1.94M sold.

Paulson & Co first reported a position in BCRX in Q1 2016 and held it in 5 quarters. The position peaked at $1.94M in Q2 2017. 120 funds tracked by Wall St. Rank hold BCRX as of Q3 2017.

  • Paulson & Co reported no remaining BioCryst Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Paulson & Co sold 349,500 BioCryst Pharmaceuticals shares in Q3 2017, an estimated $1.94M.
  • Paulson & Co first reported a position in BioCryst Pharmaceuticals in Q1 2016 and held it in 5 quarters.
  • Paulson & Co's BioCryst Pharmaceuticals position peaked at $1.94M in Q2 2017.
  • 120 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2017.

Based on Paulson & Co's 13F filing for Q3 2017, filed 14 Nov 2017.